# 2026-12904: FDA Eases Path for Restless Legs Nerve Stimulator

2026-12904, Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndrome, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-06-26, effective 2026-06-26; PRIA reads it as touching household money (as of 2026-07-03).

- Canonical: https://policyrisk.com/federal-register/2026-12904
- As of: 2026-07-03
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12904
- Title: Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndrome
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 38508
- Published: 2026-06-26
- Effective: 2026-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-03

## In one line

FDA Eases Path for Restless Legs Nerve Stimulator

## Summary

The FDA has officially placed the external lower leg nerve stimulator for Restless Legs Syndrome into a safer, easier-to-get category called Class II. This change helps patients get access to this helpful device faster while keeping safety in check. The new rules took effect on June 26, 2026, and could lower costs by cutting some red tape for makers and users alike.

## Abstract

The Food and Drug Administration (FDA) is classifying the external lower extremity nerve stimulator for Restless Legs Syndrome into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the external lower extremity nerve stimulator for Restless Legs Syndrome. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Device moved to Class II — faster access: benefit, medium. The FDA has classified the external lower extremity nerve stimulator for Restless Legs Syndrome as Class II (special controls). The order is effective June 26, 2026 (classification was applicable April 17, 2023), and FDA says this Class II classification will provide reasonable assurance of safety…
- Device is prescription-only: cost, low. The external lower extremity nerve stimulator is identified as a prescription device and is for prescription use only. That means you must obtain a prescription from a health care provider to get this device.
- De Novo ruling creates predicate for future devices: benefit, medium. FDA states that when it classifies a device into Class I or II via the De Novo process, that device can serve as a predicate for future devices. As a result, other device sponsors can use the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application.
- New special controls set testing and labeling rules: mixed, medium. FDA requires special controls for this device that include non-clinical performance testing (e.g., electrical stimulation parameters such as waveforms, maximum output voltage and current at 500 Ω, 2k Ω, and 10k Ω loads; pulse duration; frequency), electrode performance (adhesive integrity, shelf li…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-12904 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/26/2026-12904/medical-devices-neurological-devices-classification-of-the-external-lower-extremity-nerve-stimulator)
- [2026-12904 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12904.pdf)

## Related
- [Previous: 2026-12903, Medical Devices; General and Plastic Surgery Devices; Classification of the Bre…](https://policyrisk.com/federal-register/2026-12903)
- [Next: 2026-12905, Medical Devices; General Hospital and Personal Use Devices; Classification of t…](https://policyrisk.com/federal-register/2026-12905)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12904 (as of 2026-07-03).